Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Richard Peter Marshall purchased 12,183 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $1.65 per share, with a total value of $20,101.95. Following the completion of the purchase, the director owned 12,183 shares of the company’s stock, valued at $20,101.95. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Serina Therapeutics Stock Performance

Shares of SER stock traded up $0.09 during trading on Friday, hitting $1.98. The company had a trading volume of 194,287 shares, compared to its average volume of 2,913,021. The stock’s 50-day simple moving average is $1.94. The company has a quick ratio of 4.18, a current ratio of 4.18 and a debt-to-equity ratio of 0.24. Serina Therapeutics, Inc. has a one year low of $1.22 and a one year high of $7.92. The company has a market cap of $29.70 million, a price-to-earnings ratio of -0.99 and a beta of 1.15.

Serina Therapeutics (NYSEAMERICAN:SER) last released its earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.